SCHEMBL24469152

SCHEMBL24469152

Oc1nnc(CC2CCOCC2)c2ccc(Br)cc12

nearest known ligand 0.38

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 3/20 0.38
CNR1 P21554 2/20 0.38
SLC6A4 P31645 1/20 0.34
HTR6 P50406 1/20 0.34
MAPK1 P28482 1/20 0.33
SLC2A1 P11166 1/20 0.32
SLC2A2 P11168 1/20 0.32
SLC2A3 P11169 1/20 0.32
IRAK4 Q9NWZ3 2/20 0.31
MAPT P10636 2/20 0.30
LMNA P02545 1/20 0.30
HTT P42858 1/20 0.30
BLM P54132 1/20 0.30
CYP1A2 P05177 1/20 0.30
CYP2D6 P10635 1/20 0.30
CYP2C9 P11712 1/20 0.30
CYP2C19 P33261 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17824919 0.76 PRMT5 (0.50) CNR2CNR1SLC6A4MAPK1
SCHEMBL24469149 0.76 CNR1 (0.33) CNR2CNR1IRAK4MAPTLMNA
SCHEMBL24469167 0.75 P2RX3 (0.41)
SCHEMBL2462679 0.70 ALOX15 (0.42) CYP1A2CYP2C9CYP2C19
SCHEMBL24469239 0.67 POLB (0.36) SLC6A4IRAK4
SCHEMBL28850191 0.66 SLC6A4 (0.34) SLC6A4
SCHEMBL4764975 0.65 PTGES (0.33) CNR2CNR1MAPK1SLC2A1SLC2A2
SCHEMBL26732579 0.65 ALOX15 (0.38) CYP1A2CYP2C9CYP2C19
SCHEMBL30451573 0.65 ALOX15 (0.38) CYP1A2CYP2C9CYP2C19
SCHEMBL17825029 0.65 PRMT5 (0.55) SLC6A4LMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12534455-B2 Phthalazine derivatives as P2X3 inhibitors CHIESI FARMACEUTICI S.P.A. (IT) 2026-01-27 US disclosed
EP-4251273-B1 PHTHALAZINE DERIVATIVES AS P2X3 INHIBITORS CHIESI FARM SPA (IT) 2025-03-12 EP disclosed
US-20240002371-A1 PHTHALAZINE DERIVATIVES AS P2X3 INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2024-01-04 US disclosed
CN-116745284-A Phthalazine derivatives as P2X3 inhibitors 奇斯药制品公司 2023-09-12 CN disclosed
WO-2022112493-A1 PHTHALAZINE DERIVATIVES AS P2X3 INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2022-06-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12534455-B2 Phthalazine derivatives as P2X3 inhibitors P2RX3, P2RX5, P2RX7 CNR2 78/4885CNR1 75/4885SLC6A4 1428/4885
US-20240002371-A1 PHTHALAZINE DERIVATIVES AS P2X3 INHIBITORS P2RX3, P2RX5, P2RX2 CNR2 191/4885CNR1 213/4885SLC6A4 3321/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.